JWH-019
外观
| 法律規範狀態 | |
|---|---|
| 法律規範 |
|
| 识别信息 | |
| |
| CAS号 | 209414-08-4 |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| 化学信息 | |
| 化学式 | C25H25NO |
| 摩尔质量 | 355.48 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
JWH-019,化学名1-己基-3-(1-萘甲酰基)吲哚(英語:1-hexyl-3-(1-naphthoyl)indole),分子式C
25H
25NO,属于萘甲酰基吲哚类JWH系列大麻素,可作为镇痛药[2][3][4]。
参考文献
[编辑]- ^ Ustawa z dnia 15 kwietnia 2011 r. o zmianie ustawy o przeciwdziałaniu narkomanii ( Dz.U. 2011 nr 105 poz. 614 ). Internetowy System Aktów Prawnych. [12 June 2011].
- ^ Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug and Alcohol Dependence. August 2000, 60 (2): 133–40. PMID 10940540. doi:10.1016/S0376-8716(99)00152-0.
- ^ Poso A, Huffman JW. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. British Journal of Pharmacology. January 2008, 153 (2): 335–46. PMC 2219524
. PMID 17982473. doi:10.1038/sj.bjp.0707567.
- ^ Ashton JC, Wright JL, McPartland JM, Tyndall JD. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Current Medicinal Chemistry. 2008, 15 (14): 1428–43. PMID 18537620. doi:10.2174/092986708784567716.